What is actually happening today is quiet, and it's worth saying so plainly. No big deal broke. No government agency ruled on anything. The freshest thing moving through the field is a single case report — a written-up story of one patient who took ibogaine, a psychedelic made from an African plant, and afterward stopped using ketamine. That one story is doing what one story often does: it's traveling fast, catching the attention of doctors, advocates, and reporters. Meanwhile, on the stock market, one of the better-known psychedelic companies, Compass Pathways (ticker CMPS), rose 4.2% — but there's no news behind it. No trial result, no approval, no partnership. It moved on mood, not on facts.
Beneath the surface, this is really a story about the gap between a moving anecdote and solid proof. Ibogaine carries a known, serious risk: it can throw off the heart's rhythm, and people have died from it. That's why regulators — the officials who decide which drugs can be tested and sold — won't wave through access based on one patient. What's forming here is a familiar pattern. Advocates will push. Doctors may ask permission to run small studies. And officials will hold the line, asking first for careful heart-safety testing. Expect loud conversation over the next few months, but no cleared trial, no change to the law, and no proven explanation of how the medicine works. On the market side, the honest read on that CMPS bump is that it has no engine under it. It may drift back down, or it may not — without a real catalyst, the direction is simply unclear, and pretending otherwise would be guessing.
For the real people inside this, the stakes are heavy and human. Two of the hardest crises in America — addiction and the invisible wounds veterans carry home — meet inside this one patient's story. That's why a veteran might read it and feel a flare of hope: maybe there's a way out that the usual treatments never offered. That hope is not foolish. It is the reason the story matters. But the most caring thing anyone can do right now is protect these same people from a medicine that could stop their heart before it heals their mind. The highest path here is not to rush and not to dismiss. It is to take the hope seriously enough to test it properly — to fund the careful heart-safety work now, so that if this medicine truly helps, it can one day reach people safely instead of never reaching them at all.
What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone.
The current is already moving. You are already in it.
72%
Ibogaine heart-risk rules block any new ketamine-addiction trial starting
A single patient story about ibogaine helping someone quit ketamine caught attention, but turning one case into an official clinical trial takes years of safety groundwork — especially because ibogaine can cause dangerous heart rhythms. The FDA (the US drug regulator) requires companies to prove a drug won't kill people before testing it on more patients. No new ibogaine trial targeting ketamine addiction will move from idea to actively recruiting patients by late October 2026.
→ One compelling case report is nowhere near enough to get a new ibogaine trial off the ground within three months, because the drug's heart risks demand extensive safety evidence first.
Resolves: 2026-10-27 · USA
CLINICAL
the precise call ▾
The ibogaine ketamine-abstinence case report generates ≥1 new IND inquiry but no FDA-cleared trial start within 12 weeks, blocked by cardiac (QT) toxicology requirements.. Anecdotes don't clear safety review. Ibogaine's cardiotoxicity mandates preclinical packages regulators won't waive for a single case. || RESOLUTION RULE: YES if, by 2026-10-27, no new ibogaine clinical trial specifically targeting ketamine-abstinence/dependence appears with status 'Recruiting' or '
70%
COMPASS Pathways' psilocybin drug program hits no major US regulatory milestone
COMPASS Pathways is testing a synthetic psilocybin pill called COMP360 for people with hard-to-treat depression. A recent jump in their stock price wasn't driven by any real news from regulators — it was based on general excitement. Between now and October 13, 2026, the company is not expected to submit their drug for official US approval or announce any new special status from the FDA that would fast-track their program.
→ COMPASS Pathways' recent stock move wasn't tied to any real FDA milestone, and no major regulatory step forward is expected before mid-October 2026.
Resolves: 2026-10-13 · USA
CLINICAL
the precise call ▾
COMPASS Pathways' psilocybin-MDD program produces no FDA filing or breakthrough-status update within 10 weeks; CMPS's 4.2% pop is not accompanied by any regulatory milestone.. No FDA psychedelic decisions signaled today. CMPS moved on sentiment, not de-risked catalyst. My review calendar has no near-term psilocybin action. || RESOLUTION RULE: YES if, between 2026-08-04 and 2026-10-13, COMPASS Pathways (ticker CMPS) issues no press release/IR announcement of an FDA filing
70%
One ibogaine case report won't change US drug laws or expand legal access
Ibogaine is currently a Schedule I substance in the US — the most restricted category, meaning the government considers it to have no accepted medical use and high abuse potential. One published patient story won't prompt the DEA (the US Drug Enforcement Administration) to loosen that classification, and the FDA won't open a formal compassionate-use program (a special pathway letting seriously ill patients try unapproved drugs) based on a single anecdote. Ibogaine's history of causing fatal heart problems gives regulators every reason to move slowly.
→ A single case report simply cannot move US drug policy — ibogaine stays in the most restricted legal category with no new access pathways opening before late October 2026.
Resolves: 2026-10-27 · USA
POLICY
the precise call ▾
The ibogaine case report yields no DEA scheduling accommodation and no cleared expanded-access pathway within 12 weeks; cardiac-risk framing dominates any official response.. One anecdote doesn't move Schedule I. Ibogaine's fatality record gives us every reason to hold the line on controlled access. || RESOLUTION RULE: YES if, by 2026-10-27, no FDA expanded-access (compassionate-use) program for ibogaine is publicly listed and no DEA Federal Register notice altering ibog
68%
No rigorous science on how ibogaine and ketamine interact will emerge soon
Scientists don't yet understand the biology of why ibogaine might help someone stop using ketamine — the one published case offers a story, not an explanation. Properly designed studies that could actually test a mechanism (like a controlled experiment with a comparison group) take months or years to fund, design, and launch. By late October 2026, any follow-up work will almost certainly still be observational — meaning researchers watching and recording what happens naturally, not running a controlled experiment.
→ The science needed to understand how ibogaine and ketamine interact in the body simply doesn't exist yet, and it won't be done within three months.
Resolves: 2026-10-27 · Global
RESEARCH
the precise call ▾
The ibogaine-ketamine case report prompts no validated mechanistic study; any follow-up remains observational, not controlled, within 12 weeks.. Mechanism requires funded controlled work that isn't in place. The field will over-interpret an anecdote before the biology is understood. || RESOLUTION RULE: YES if, by 2026-10-27, no controlled (randomized or mechanistic in-vivo/interventional) study on ibogaine-ketamine interaction is published o
63%
COMPASS stock likely falls back and no psychedelic company mergers happen soon
When a stock jumps without a concrete reason — like a major trial result or a partnership deal — it usually drifts back down. COMPASS Pathways' recent 4.2% gain fits that pattern. Meanwhile, none of the major publicly traded psychedelic companies (COMPASS, ATAI Life Sciences, Mind Medicine, or Numinus) appear to be in merger or acquisition talks. Without a real catalyst — new data, a buyout, or a licensing deal — the pop is expected to erase itself by August 25, 2026.
→ Catalyst-free stock pops almost always reverse — expect COMPASS's recent gain to disappear within three weeks unless real news arrives.
Resolves: 2026-08-25 · Global
MARKETS
the precise call ▾
CMPS gives back the majority of its 4.2% gain within 15 trading days absent a data or partnership catalyst; no M&A among CMPS/ATAI/MMED/NUMI in 8 weeks.. Catalyst-free pops mean-revert. The sector trades on Phase 3 readouts and licensing deals — none pending among these names near-term. || RESOLUTION RULE: YES if CMPS closing price on 2026-08-25 is at or below its 2026-08-01 close (i.e. the 4.2% pop is fully retraced) AND no announced M&A/acquisition